| News

Novaremed secures US$50 million

03.02.2021

Basel biotech Novaremed is receiving US$50 million through an agreement with an investment group. Novaremed will use this financing to progress the clinical development of its treatment for painful diabetic peripheral neuropathy.

The Luxembourg-based investment group GEM Global Yield has committed to provide Novaremed with up to US$50 million over a 36-month term. In return, GEM will have the right to purchase shares of Novaremed following the public listing of the company, as was explained in a press release from the Basel biotech. Novaremed will control the timing and maximum amount of drawdown under this share subscription facility.

“This funding agreement with GEM will help us, upon the company’s public listing, to advance our highly innovative lead product that we are developing for the non-opioid treatment of patients affected by diabetes-related chronic neuropathic pain,” said Isaac Kobrin, Executive Chairman of the Board of Novaremed, in the press release. His company was founded in Israel in 2008 and set up in Basel at the end of 2017. Basel Area Business & Innovation, the investment and innovation promotion agency, supported Novaremed in making the move.

Novaremed’s lead product, NRD135S.E1, is an investigational non-opioid small molecule drug for the treatment of painful diabetic peripheral neuropathy. Patients suffering from this experience a painful burning or tingling sensation in areas such as the hands or feet and lower legs. This debilitating neuropathic pain substantially impairs quality of life. Given the ongoing opioid crisis with addiction to pain medication a growing problem, the non-opioid drug developed by Novaremed is a novel alternative treatment.

GEM’s investment represents the largest funding round for a Swiss startup this January, as was reported in a press release on the Startup.ch platform about the latest Swiss Venture Capital Report. Startups from the Basel Area also received the most financing of all regions.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

MTIP using new fund to invest in innovative companies
Basel Area Business & Innovation, Innovation, Invest

MTIP using new fund to invest in innovative companies

The Basel-based firm MTIP AG specializes in investments in HealthTech companies. A total of 130 million euros has already been...

Read More
Basel Area records successful 2020
Basel Area Business & Innovation, Innovation, Invest

Basel Area records successful 2020

Basel Area Business & Innovation was able to newly settle a total of 27 companies in the Basel Area in...

Read More
BetterDoc opts for Basel
Basel Area Business & Innovation, Innovation, Invest

BetterDoc opts for Basel

The online medical service BetterDoc has selected Basel as its Swiss location. Together with the health insurance firm Assura, it...

Read More
RN Laboratories arrives in the Basel Area
Basel Area Business & Innovation, Invest

RN Laboratories arrives in the Basel Area

The global Indian chemicals firm RN Laboratories is establishing a presence in Muttenz. The company will also be building a...

Read More
Kybora settles its European headquarters in Basel
Basel Area Business & Innovation, Innovation, Invest

Kybora settles its European headquarters in Basel

The American consultancy Kybora, which operates within the life sciences industry, has established its European headquarters in Basel. Kybora GmbH...

Read More
Escientia establishes subsidiary in the Basel Area
Basel Area Business & Innovation, Innovation, Invest

Escientia establishes subsidiary in the Basel Area

The U.S. company Escientia Life Sciences Group has established a subsidiary in the canton of Basel-Landschaft. Escientia Switzerland will offer...

Read More
1 2 3 42

Do you have a question? We'd like to hear from you.